Transurethral enucleation and resection for treating recurrent benign prostatic hy- perplasia

Objective To introduce the method and the clinical efficacy of transurethral enucleation and resection of the prostate(TUERP)to treat recurrent benign prostatic hyperplasia(BPH).Methods During Jan.2008 to Jan.2012,78 BPH patients who had undergone transurethral resection of prostate(TURP)received TUERP for recurrent BPH.The international prostate symptom score(IPSS),maximum urine flow rate(Qmax),post-void residual urine volume(PVR),quality of life(QOL),prostate specific antigen(PSA)before operation and 6 months after operation were compared.Results Of the 78 cases,2 were complicated with temporary urinary incontinence,and1 with anterior urethra stricture.The pre-operation IPSS, QOL,Qmax,PVR,PSA were 21.9±4.5,4.1±0.6,(6.2±2.9)mL/s,(93.6±50.1)mL,(3.58±2.76)ng/mLrespectively; the post-operation values were 4.7±2.4,0.8±0.5,(19.7±3.2)mL/s、(10.5±6.3)mL、(0.91±0.64)ng/mL.Significant statistics difference(P0.01)were observed between pre-and post-data.Conclusions TUERP is safe and effective in the treatment of recurrent BPH.The key to this surgery is looking for prostatic surgical capsule plane and prostate stripping.